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Abstract 
The pharmaceutical industry is currently facing a high clinical attrition rate.  In order to 
prevent the late-stage clinical failure, many investigations on compound quality and drug-
likeness of compounds have been carried out.  It has been widely accepted that molecular size 
and lipophilicity plays an important role in compound quality.  Many attempts have been done 
to find out other factors which can influence compound quality beyond size and lipophilicity. 
Recently, a molecular topology concept has been put forward and its influence on compound 
quality has been investigated.  It has been shown that drugs have higher fraction of 
compounds with only one ring system compared to clinical candidate and bioactive 
compounds.  As an extension to the previous studies, the aim of this project is to further 
investigate how the molecular topology influences some of the most important 
physicochemical properties of molecules as well as the compound potency efficiency indices 
in general.  Our results show that among reported molecules in the literature, compounds with 
only one ring system are smaller in size, less lipophilic and therefore has a higher probability 
to be less toxic.  Interestingly compounds which have a simple topology also show advantage 
in terms of potency efficiency such as ligand efficiency (LE), ligand lipophilic efficiency 
(LLE) and ligand-efficiency-dependent lipophilicity index (LELP) compared with compounds 
which have a more complex topology.  Thus a novel hypothesis why compounds with only 
one ring system are abundant among drugs has been proposed. On average molecules with 
only one ring system seems to bind more strongly to its protein target; this might reduce the 
necessary size of the molecule to reach a certain potency level. The reduction in size and 
lipophilicity reduces the risk of failure in clinical trials. 
 
Introduction 
Drug discovery and development is a time consuming process which typically takes 15 to 20 
years from the target identification until a drug makes it to the market.  During this lengthy 
process, numerous compounds are tested, synthesized and validated in order to achieve the 
optimal efficacy and safety profile.  Firstly, a potential target causing a disease is identified; 
the target may be over-expressed, under-expressed or mutated in a patient.  Then, many 
compounds are screened for an interaction to the target to discover “hit” compounds, which 
will be starting molecules for the whole drug development process.  The identified “hits” may 
have undesirable side-effects or may not have good bioavailability; the potency and 
bioavailability of compounds are improved and promiscuity is minimized.  The compounds 
are now called “lead” compounds and their efficacy of lead compounds are examined in 
animal models before they are further optimized.  Once the compounds’ safeties are assured, 
they can be tested in clinical trials: Phase I assess the safety in a few healthy individuals, 
Phase II assesses the efficacy in a small group of patients, and Phase III extends the 
assessment to a larger group of patients.  Only compounds passed phase III will be registered 
as a drug and will be on market.   
Historically drug discovery was an iterative process of compound synthesis and in vivo 
screening.  This paradigm has changed by the advancement of in vitro high-throughput 
screening technology and in silico techniques.  Now computational methods are commonly 
used from target identification to lead optimization: gene sequence analysis and gene 
expression analysis find out potential targets, virtual screening discovers hit compounds and 
structural analysis suggests possible ways of compound optimization, for example.  Another 
use of a computational method is to predict compound quality; by estimating physicochemical 
properties and bioavailability in an early stage and avoiding the advancement of compounds 
with poor basic properties, it is possible to reduce the number of late stage failure.   
The paradigm shift has largely improved hit identification efficiency; however the 
pharmaceutical industry still faces a high attrition rate.  It was estimated by U.S. Food and 
Drug Administration (FDA) that eventually only 8 % of the compounds entering to Phase I 
can reach the market.
[1]
  In order to decrease the late-stage clinical attrition, it is critical to 
identify compounds which are unlikely to succeed and to terminate the development of these 
compounds as early as possible.  The most important properties for a drug molecule are so 
called ADMET (absorption, distribution, metabolism, excretion and toxicity) properties, and 
they are investigated at an early stage in the drug development process.  Only compounds 
with a good ADMET property profile should be advanced to the clinical trial.   
The well-known Lipinski’s Rule of Five was proposed to assess the oral bioavailability of a 
compound.
[2]
 It defines cutoffs for molecular mass, lipophilicity, number of hydrogen bond 
donors and acceptors which captures 90% of oral drugs and clinical candidates.
[2-4]
  Despite 
the fact that Rule of Five is often used as a filter, a number of drug compounds violates one or 
more criteria,
[2]
 therefore this should be kept as a guideline for bioavailability estimation. As 
mentioned in the Lipinski’s Rule of Five, the importance of lipophilicity and molecular size is 
widely accepted.  Leeson and Springthorpe observed that high promiscuity, as well as other 
ADMET liabilities including low solubility, high plasma protein binding (PPB), and high 
hERG (human ether-ago-go-related potassium channel protein) inhibition,
[5]
 can be caused by 
high lipophilicity.  Low solubility and high PPB leads to low free plasma concentration of the 
compounds, which is critical to get desired pharmacology effect.  hERG is a voltage gated 
potassium ion channel, and high inhibition of this protein can cause QT prolongation which 
may result in fatal cardiac arrhythmia.
[6]
  Comparison of several simple physicochemical 
properties analysis done by Wenlock et al. showed that drugs have significantly lower 
lipophilicity and molecular size than general bioactive compounds, compounds which have 
effects on living systems, and clinical candidates.
[7]
   
Another important factor considered during the drug development process is potency.  
Potency has an influence on the amount of dose in most cases; low potency requires high 
concentration of the drug compound which increases the risk of toxic response.  It has been 
observed that there is a strong correlation between the molecular size and the potency,
[8-10]
  
and Ligand Efficiency (LE) has been introduced to correct the potency for the molecular size 
by dividing by the heavy atom numbers.  The use of this index enables to prioritize small 
molecules with lower potency rather than large molecules with higher potency.
[11,12]
  Even 
though LE still has some size bias,
[8,9,13]
 this index is widely accepted to assess the ligand 
affinity and practically used.  Another useful factor related to the potency is Ligand 
Lipophilicity Efficiency (LLE) investigated by Leeson and Springthorp.
[5]
  There is a general 
trend of increase in potency during the drug development process which also increases the 
lipophilicity.
[10,14]
  As discussed earlier, lipophilicity should be kept low to avoid the ADMET 
liabilities and potential promiscuity; LLE is a useful index to improve potency while 
controlling the lipophilicity at the same time.  While LE and LLE are two indices that 
complement each other, Ligand-Efficiency-dependent LipoPhilicity (LELP) is another 
potency efficiency index which correlates both lipophilicity and molecular size.  It has been 
shown a single score combined molecular mass and lipophilicity provides better prioritization 
of compounds than individual parameter cut-off rules.
[10]
 Drugs display significantly lower 
LELP value than general hits, leads and phase II clinical candidates, while it is not always the 
case for LLE.
[14]
   
Several investigations have been carried out to find out other compound quality criteria 
beyond molecular size and liphophilicity.  Ritchie et al. observed the negative impact of a 
large number of aromatic rings in a molecule on the compound quality,
[15]
 and Lovering et al. 
reported higher fraction of sp3 hybridized carbon atoms and the presence of chiral centers 
increases the clinical success rate.
[16]
  These two observations complement each other.   
Recently molecular topology class was proposed
[17]
 as an extension of molecular framework 
proposed by Bemis and Murcko.
[18]
  The advantage of this molecular topology class is that 
this classification divides compounds into only a few topological classes compared to the 
earlier molecular framework, and therefore it is possible to apply rigorous statistical tests on 
the results.
[17]
  This classification defines the terminal rings (TR), molecular bridge (B) and 
side chains, and the number of terminal rings and molecular bridge determines the molecular 
topology class of the molecule.  It has been reported that the fraction of compounds with only 
one ring system is higher in drugs compared to clinical candidates and general bioactive 
compounds.
[17]
  This trend is still valid after correcting for lipophilicity, molecular size, and 
potential target bias in the data set.
[19]
  fMF is another descriptor which related to the concept of 
molecular topology; it is the fraction of molecular framework, which consists of terminal 
rings and molecular bridge.  It has been shown that fMF correlates to the ADMET properties, 
such as solubility, permeability and Cytochrome P450 isoform 3A4 inhibition, as well.
[20]
   
The previous study results have demonstrated that the molecular topology has some influence 
on the compound quality and drug-likeness of the compounds; however, the influence of 
molecular topology on ADMET properties and potency is still unknown.  This project 
examined the correlation between molecular topology and ADMET experimental data as well 
as the three potency efficiency indices to better understand the earlier observation of 1TR 
compounds’ enrichment in drugs.    
 
Methods 
Data Sets:  
For the Cytochrome P450 isoform 3A4 (CYP3A4) inhibition data analysis, a dataset of 
15,887 compounds was used from the AstraZeneca in-house collection. 
For the compound quality indices analysis, the data set was retrieved from GVKBIO, a 
commercial database where activity data has been extracted from medicinal chemistry 
journals and patents.
[21]
  Only compounds associated with human targets were selected.  
Altogether, the data set includes in total 1,022,057 data points which correspond to bioactivity 
data of 695,322 unique structures for 972 human targets.  
Definition of molecular topology classes: 
Figure 1. Examples of different topological classes. (TR = Terminal Rings, B = Bridge).  
Purple is showing the terminal rings and orange is showing the molecular bridges in each 
compound.   
The concept of molecular topology class
[17] 
is based on an earlier molecular framework 
analysis.
[18]
  A molecule can be divided into three subunits: terminal ring system (TR), 
molecular bridge (B), and side chain.  A terminal ring system is defined as a cyclic structure 
which has only one connection to other ring structures in the molecule.  The molecular bridge 
is a linker that connects the terminal ring systems and it may include ring systems.  Side 
chains refer to the parts of the molecule which do not belong to neither of the two other 
subunits.  The topology class for any given compound is therefore depending on the number 
of terminal ring systems and the presence or absence of a molecular bridge.  Some examples 
of different topological classes are shown in Figure 1.  The 2TR+B class was subdivided 
according to the number of ring systems in molecular bridge to further enhance the analysis.  
In this study, the classes of 1TR, 2TR, 2TR+B and 3TR+B were considered. More 
complicated classes such as 4TR+B, 5TR+B were excluded due to their low occurrence in the 
dataset.   
Property Calculations:  
For all compounds, the ionization state was determined by substructure matching of a set of 
predefined acidic, basic and cationic functional groups with an in-house program.  ClogP was 
calculated using the commercial available Biobyte ClogP program.
[22]
  Molecular topology 
classes and the number of heavy atoms (i.e., non-hydrogen atoms) were calculated with an in-
house C++ program based on the OpenEye toolkit.
[23]
  The ring system complexity (RSC) is 
calculated by subtracting number of ring systems from the number of smallest set of smallest 
rings (SSSR).
[17,24]
  The descriptor fMF is defined as: 
fMF = HEVMF / HEVtotal   (Equation 1) 
Where HEVMF is the number of heavy atoms in the molecular framework and HEVtotal 
is the number of heavy atoms in the whole molecule.  
The calculation steps are also shown in Figure 2 for fMF.   
 
Figure 2. fMF can be calculated with the following steps: identify the molecular frame work 
from the original molecule and count the number of heavy atom(HEV), and divide the number 
by the total heavy atom number.  With this example in the figure, 10 HEV for molecular 
framework, and 20 for the whole molecule; thus fMF = 10 / 20 = 0.5. 
Ligand Efficiency (LE), Ligand Lipophilic Efficiency (LLE) and Ligand-Efficiency-
dependent LipoPhilicity (LELP) are defined and calculated using Equation 2, 3 and 4 
accordingly.   
LE = ∆G / HEV    (Equation 2) 
Where ∆G = -RT ln IC50, and HEV is the number of heavy atoms.   
LLE = pIC50 – ClogP   (Equation 3) 
LELP = ClogP / LE    (Equation 4) 
All statistical analysis of Wicoxon rank-sum test
[25]
 was performed with the open source 
statistic package, Python-statlib.
[26]
   
 Results and Discussion 
CYP3A4 inhibition analysis:  
Cytochrome P450 is a family of enzymes which is involved in drug metabolism and other 
reactions in cholesterols, steroids, and lipids synthesis.  CYP3A4 is one of the most abundant 
isoforms
[27]
 and it metabolizes approximately half of the drugs used today.
[28]
  Multidrug 
administration can cause competing drug-metabolism (drug-drug interaction) which can lead 
to a high drug concentration with a higher probability of toxic response.
[29]
  It is therefore 
important to monitor and screen for CYP3A4 inhibition.  Previously, it has been shown high 
lipophilicity, large molecular size and large fMF correlates with CYP3A4 inhibition.
[20]
   
This study investigated how the CYP3A4 inhibition correlates with the molecular topology 
classes.  1TR compounds showed lower CYP3A4 inhibition compared to more complicated 
compounds, such as 2TR+B and 3TR+B.  Further analysis showed the correlation of 
molecular size and fMF with the molecular topology class, and the cross-correlation of the 
descriptors.  From these observations, it was concluded that 1TR compounds’ lower CYP3A4 
inhibition is a combinatorial effect of small molecular size and low fMF.   
For further details of results and analyses, see the manuscript “An investigation of the 
relationship between molecular topology and CYP3A4 inhibition for drug-like compounds” 
which is appended.  The manuscript is submitted for publication. 
Compound quality indices analysis:  
Even though CYP3A4 inhibition is an important property in the drug development process, 
CYP3A4 inhibition plays probably only a minor role in explaining why 1TR compounds are 
abundant among drugs compared to other compound collections.  For a better understanding 
of the higher fraction of 1TR compounds among drugs, the potency distribution over 
molecular topology classes and the correlation between three compound quality indices, LE, 
LLE and LELP, and molecular topology classes was investigated.   
In this investigation, it was observed that the reported potency data in the literature is 
independent from both lipophilicity and molecular size.  It is shown that 1TR compounds 
have better values of LE, LLE and LELP compared to the other topological classes; this 
conclusion is still valid after correcting for any potential bias due to that the compounds from 
different topological classes might be reported to be active on different targets.  Two different 
factors contribute to this novel result. 1TR compounds are much more frequent among the 
reported compounds with small size and low lipophilicity. Thus when a potent compound is 
identified with low lipophilicity and small size in a drug discovery project, it is often 
compounds from the 1TR topology class. The second factor is that at constant size 1TR 
compounds have higher potency than other compounds. Thus it is easier to reach a desired 
potency with a compound belonging to the 1TR topology class that has small size and 
lipohilicity. The reduced size and lipophilicity will then contribute to a lower clinical attrition 
rate and accordingly to an enrichment of compounds with a 1TR topology among drugs.  
For further details of results and analyses, see the manuscript “The influence of molecular 
topology on compound quality indices like ligand efficiency and ligand lipophilic efficiency” 
which is appended. The manuscript will be submitted for publication soon.   
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Abstract 
Earlier studies have shown that CYP3A4 inhibition is influenced by lipophilicity, 
size and fMF, where fMF is the size of the molecular framework divided by the total size of the 
molecule. Other previous study has shown that there is an enrichment of compounds with 
only one ring system among drugs in comparison to clinical candidates and general bioactive 
compounds as well as enrichment among natural products and human metabolites compared 
to general bioactive compounds. Thus a logical extension of the earlier investigations would 
be to study how ring systems influence CYP3A4 inhibition. It is shown here that compounds 
with only one ring system have lower CYP3A4 inhibition compared to compounds with 
several ring systems. This is due to that they are both smaller and have smaller fMF compared 
to compounds with several ring systems. The investigation provides additional insights how a 
molecule should be constituted to have low CYP3A4 inhibition and may influence library 
design and compound acquisitions. 
 
Keywords: CYP3A4 inhibition; Molecular topology class; ADMET; fMF; Fsp3; Drug-
likeness 
 The pharmaceutical industry faces a high attrition rate for compounds entering 
clinical development. Only a small fraction of them passes all the development hurdles to 
become approved drugs.
[1]
 In order to reduce the number of costly late-stage clinical failures, 
it is critical to filter out compounds which have ADMET (absorption, distribution, 
metabolism, excretion, and toxicity) liabilities as early as possible. For instance, Lipinski 
proposed the well known “rule of five” as a useful filter to assess the likelihood of oral 
bioavailability.
[2,3]
 The lipophilicity and the molecular size are widely regarded as important 
factors influencing the drug-likeness
[4-7]
. High lipophilicity increases the promiscuity in 
addition to other liabilities such as low solubility, high plasma protein binding and high hERG 
inhibition.
[4]
 Recently a comparison of several simple physicochemical properties for 
marketed drugs, clinical candidates and bioactive compounds was performed, where any 
potential bias due to target class differences was removed.
 
The study confirmed that the 
lipophilicity is lower and the molecular size is smaller for drugs than for clinical candidates 
and general bioactive compounds.
[5]
 
Further investigations have been carried out to identify additional factors affecting 
the compound quality. For example, the fraction of sp3 carbon atoms (Fsp3) and the presence 
of chiral centers are correlated with clinical success.
[8]
  Also a large number of aromatic rings 
can negatively impact several drug-like properties.
[9]
 It has also been shown that the 
molecular topology influences the promiscuity.
[10]
 In another recent study it was investigated 
how ADMET is influenced by molecular size, lipophilicity, ionization state, Fsp3 and fMF.
[11]
 
fMF is defined as the size of the molecular framework divided the total size of the molecule.
[10]
 
It was shown that high lipophilicity, large size and large fMF correlate with Cytochrome P450 
isoform 3A4 (CYP3A4) inhibition. However, Fsp3 did not show any significant correlation 
with CYP3A4 inhibition. While it is important to correlate simple descriptors to CYP3A4 
inhibition, the descriptors give only a rudimentary understanding of how a molecule should be 
constituted to have a low CYP3A4 inhibition. The descriptors like size, lipophilicity and fMF 
can be used in lead optimization to modify a molecule which leads to reduced CYP3A4 
inhibition. However, these descriptors are rather abstract and it would be useful to more 
thoroughly understand what types of molecular topologies that have lower CYP3A4 
inhibition. A more thorough understanding of the molecular topology can guide library 
designs and compound acquisitions to lower potential CYP3A4 liabilities in a compound 
collection. It is not always possible to do major changes to the molecular topology during lead 
generation and optimization so it is important that the starting molecule has a suitable 
molecular topology. It is therefore of interest to correlate CYP3A4 inhibition to different 
molecular topologies in order to enhance the understanding of the relationship between 
molecular structure and CYP3A4 inhibition.  
An extension of the molecular framework analysis has recently been proposed. In 
the new method, a molecule is partitioned into only a few different classes based on the 
molecular topology.
[12-13]
 A topology class analysis comparing drugs, clinical candidates and 
general bioactive compounds has shown that in comparison with clinical candidates and 
bioactive compounds, drugs have a higher fraction of compounds with only one ring system.
 
[12]
 This conclusion is still valid after correcting for any bias originating from lipophilicity 
(ClogP), molecular size and target class.
[12]
 The main advantage of the topology class analysis 
is because it classifies a molecule into only a few different classes, while in comparison 
earlier molecular framework analysis created many more different topologies.
[14]
 Thus it is 
possible to apply rigorous statistical methods to the obtained results, while still providing 
important information of the relationship between the molecular topology and CYP3A4 
inhibition. 
According to the definition of topology class, a molecule is partitioned into three 
different subunits: terminal ring systems (TR), a molecular bridge (B), and side chains. A 
terminal ring system is defined as a cyclic structure which has only one connection to other 
ring structures. The molecular bridge is the linker which connects the terminal ring systems. 
The molecular bridge might also include additional ring systems. Side chains refer to the parts 
that do not belong to the other two parts. The molecular framework consists of the terminal 
ring systems and the molecular bridge. The topology class for a given compound depends on 
the number of terminal ring systems and the presence (or absence) of a molecular bridge. 
Examples of different topology classes are shown in Figure 1. The 2TR+B class can be 
further subdivided according to the number of ring systems in the molecular bridge. For 
example, the 2TR+B_1 class compound consists of two terminal rings and a molecular bridge 
and there is additionally one ring system in the molecular bridge. 1TR, 2TR, 2TR+B and 
3TR+B classes were used in the analysis. More complicated classes such as 4TR+B and 
5TR+B were excluded due to their low occurrence in the used dataset. 
Earlier investigations has shown that 1TR compounds are more common among drugs 
in comparison to clinical candidates and general bioactive compounds, this result was still 
valid after correcting for size, lipophilicity and any bias due to differences in activities on 
different targets.
[12]
 Additionally it has been shown that 1TR compounds is also common 
among natural products and human metabolites.
[13]
 Thus it seems that 1TR is a preferred 
molecular topology in nature. It is of interest to broaden the investigation of molecular 
topology into ADME properties to further enhance the knowledge between molecular 
topology and drug-likeness. Further studies can give additional understanding if compounds 
with 1TR are suitable starting points for drug discovery projects, which is suggested by the 
earlier results.  
CYP3A4 is a gene encoding a member of the Cytochrome P450 superfamily of 
enzymes. The CYP3A4 enzyme catalyzes many reactions involved in drug metabolism and 
synthesis of cholesterol, steroids and other lipids and is the most abundant Cytochrome P450 
isoform
[14]
 and is involved in the metabolism of approximately half of the drugs in use 
today.
[15]
  Multidrug administration can cause competing metabolism of drugs (so called drug-
drug interaction), which might lead to an increased blood concentration of the drugs with an 
accompanying higher probability of toxic side effects.
[16]
 It is therefore important to 
investigate CYP3A4 inhibition early in a drug discovery project. A dataset of 15,887 in-house 
compounds was used in the current study. The relationships between size, lipophilicity and 
fMF and CYP3A4 inhibition for this dataset have already been reported.
[11]
 However, since the 
format of the reported figures is different than the format used in this study, the results are 
shown in the format used here in Figure S1.  
For all compounds in the data set, the ionization state was determined by substructure 
matching of a set of predefined acidic, basic and cationic functional groups. ClogP was 
calculated with a commercial program.
[17]
 Molecular topology class and the number of heavy 
atoms were determined with an in-house C++ program based on the OpenEye toolkit.
[18]
 All 
statistical analysis was done with the open source statistics package  Python-statlib.
[19]
 
In the current study, the relationship between the topology class and CYP3A4 inhibition 
has been investigated. The results show that the molecular topology class has a distinct 
influence on CYP3A4 inhibition. The CYP3A4 inhibition for each topology class is shown in 
Figure 2. 1TR compounds have on average lower inhibition than compounds from the other 
topological classes. The Wilcoxon rank-sum test
[20]
 shows that the differences in CYP3A4 
inhibition between the compounds in the 1TR class and the compounds from the other 
topological classes are statistically significant (Table S1). Molecules with two ring systems 
(2TR and 2TR+B_0) have also on average lower inhibition than molecules with three ring 
systems. To exclude any potential bias in the results originating from differences in ionization 
state, the whole dataset was partitioned into four groups according to the ionization state 
(acidic, basic, neutral and zwitterionic). The most common ionic species are basic and neutral 
compounds (Figure 3). For both basic and neutral compounds, 1TR compounds have lower 
CYP3A4 inhibition than compounds from the other topology classes. Thus any potential bias 
due to the ionization state for the obtained results in this study is excluded. Again, the 
Wilcoxon rank-sum test shows that the differences in CYP3A4 inhibition between compounds 
in the 1TR class and the compounds from the other topological classes are statistically 
significant (Table S2). 
As shown in an earlier study, 
[11]
 the CYP3A4 inhibition is influenced by ClogP, size 
and fMF. CYP3A4 inhibition increases with increasing ClogP, size and fMF. The relationship 
between the three descriptors and the topology classes were therefore thoroughly investigated. 
As is seen in Figure 4, there are only small differences in lipophilicity between the different 
topological classes. However, there is a significant difference in size; 1TR compounds are on 
average significantly smaller than compounds from the other topological classes. Compounds 
with two ring systems are also on average smaller than compounds with three ring systems. 
Thus there is a correlation between the number of ring systems and the molecular size. 
Compounds in the 1TR class have on average smaller fMF than compounds from the other 
topological classes, i.e. compounds in the 1TR class have larger and/or more side chains than 
compounds from the other topological classes. Again compounds with two ring systems are in 
between compounds with one and three ring systems. As it has been earlier observed that an 
increase in molecular size and fMF also increases the CYP3A4 inhibition,
[11]
 the small size and 
small fMF for 1TR compounds might explain their low CYP3A4 inhibition. The statistical 
significance tests are shown in Table S3. 
It is of interest to deepen the understanding of how the three descriptors analyzed 
influence CYP3A4 inhibition and to investigate if there are some cross correlations between 
them that give rise to the low CYP3A4 inhibition for compounds in the 1TR class. First it was 
investigated if the observed differences in CYP3A4 inhibition between the topological classes 
are independent of the three descriptors individually. If the differences are independent, we 
need to investigate if there is a cross correlation between the descriptors that explains the 
observed relationships. As is shown in Figures S2-S4, the differences in CYP3A4 inhibition 
between the topology classes are mainly independent of the ClogP, size and fMF, respectively. 
However, there is an increased level of noise in the data for bins populated with only a small 
number of compounds. There is a strong correlation between size and fMF for a topological 
class (Figures S5-S6). For a fixed molecular size, fMF is much smaller for compounds with 
fewer ring systems. Since compounds in the 1TR topological class have only one ring system, 
they have on average also the smallest fMF. Thus the most likely reason that compounds in the 
1TR topological class have low CYP3A4 inhibition is because they are both smaller and have 
a lower fMF than compounds from the other topological classes. In conclusion it has been 
shown that the size is correlated with the number of ring systems and accordingly 1TR 
compounds are smaller than 2TR+B_0 compounds, which are smaller than 2TR + B_1 and 
3TR+B compounds. Additionally, for a constant molecular size, 1TR compounds have a 
lower fMF i.e. they are likely to have larger part of the molecule that are not part of the 
molecular framework in comparison with compounds from the other topology classes, 
It is important for future drug discovery projects to further enhance the understanding of 
how a molecular should be constituted to have better ADME properties. In this study we have 
therefore investigated how the molecular topology affects CYP3A4 inhibition. It is essential 
in this type of analysis to balance the need to better understand the relationship between 
CYP3A4 inhibition and molecular topology with the need to be able to perform rigorous 
statistical analysis. We have therefore decided to divide our dataset into just a few topological 
classes which allows a statistically valid comparison of CYP3A4 inhibition between different 
topology classes. In conclusion it was found that compounds in the 1TR class have lower 
CYP3A4 inhibition than compounds from the other topological classes. This is due to a 
combination of smaller size and lower fMF for compounds in the 1TR topology class. The 
same explanation can be used to rationalize why compounds with two ring systems have 
lower CYP3A4 inhibition than compounds with three ring systems. Further investigations will 
be needed to understand the relationship between the molecular topology class and other 
properties related to drug-likeness. In conclusion, descriptors found earlier to influence 
CYP3A4 inhibition has here been interpreted from a topology perspective, it was found that 
molecules with fewer ring systems, preferably only one, is most common among compounds 
with low CYP3A4 inhibition. As has been reported earlier 1TR compounds are over-
represented among drugs and human metabolites, the found results here gives additional 
support in prioritizing 1TR type compounds in library design and compound acquisitions to 
enrich a compound collection. 
 
Supporting Information available: Figures S1-S6 and Tables S1-S3 are appended as 
Supporting Material.  
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Figure 1. Examples of different topological classes. (TR = Terminal Rings, B = Bridge).  The 
purple color is emphasizing the terminal rings and the orange color is emphasizing the 
molecular bridge for each compound.   
  
  
 
Figure 2. The relationship between CYP3A4 inhibition and the different topological classes.   
 
  
(a) 
 
(b) 
 
Figure 3. (a) Relationship between the topological classes and CYP3A4 inhibition for basic 
and neutral compounds, and (b) the distribution of different ionization states for each 
topological class.  
  
(a) ClogP 
(b) HEV 
(c) fMF 
Figure 4. The relationship between the molecular topology classes and (a) ClogP, (b) Heavy 
atom count (HEV) and (c) fMF.  
  
 (a) ClogP 
(b) HEV 
(c) fMF 
Figure S1. The relationship between CYP3A4 inhibition (pIC50) and (a) ClogP, (b) Heavy 
atom count (HEV) and (c) fMF.  
(a) ClogP ≤ 2.00 (b) 2.00 < ClogP ≤ 3.00 
(c) 3.00 < ClogP ≤ 4.00 (d) ClogP > 4.00 
Figure S2. The relationship between the molecular topology classes and CYP3A4 inhibition 
(pIC50) for different ClogP intervals.   
  
(a) HEV ≤ 19 (b) 19  < HEV ≤ 21 
(c) 21 < HEV ≤ 23 (d) 23 < HEV ≤ 25 
(e) HEV > 25 
 
Figure S3. The relationship between the molecular topology classes and CYP3A4 inhibition 
(pIC50) for different Heavy atom count (HEV) intervals.    
(a) fMF ≤ 0.50 (b) 0.50 < fMF ≤ 0.60 
(c) 0.60 < fMF ≤ 0.70 (d) 0.70 < fMF ≤ 0.80 
(e) 0.80 < fMF ≤ 0.90 (f) fMF > 0.90 
Figure S4. The relationship between the molecular topology classes and CYP3A4 inhibition 
(pIC50) for different fMF intervals.    
(a) HEV ≤ 19 (b) 19  < HEV ≤ 21 
(c) 21 < HEV ≤ 23 (d) 23 < HEV ≤ 25 
(e) HEV > 25 
 
Figure S5. The relationship between the molecular topology classes and fMF for different 
Heavy atom count (HEV) intervals.    
(a) fMF ≤ 0.50 (b) 0.50 < fMF ≤ 0.60 
(c) 0.60 < fMF ≤ 0.70 (d) 0.70 < fMF ≤ 0.80 
(e) 0.80 < fMF ≤ 0.90 (f) fMF > 0.90 
Figure S6. The relationship between the molecular topology classes and Heavy atom count 
(HEV) for different fMF intervals.    
Table S1. p-values calculated with the Wilcoxon rank-sum test displaying the statistical 
significance of the differences in CYP3A4 inhibition between the different molecular 
topological classes.  
 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR 
1TR <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
2TR - 0.1863 <0.0001 <0.0001 <0.0001 
2TR+B_0 - - <0.0001 <0.0001 <0.0001 
2TR+B_1 - - - <0.0001 <0.0001 
2TR+B_2 - - - - 0.0013 
  
Table S2. p-values calculated with the Wilcoxon rank-sum test displaying the statistical 
significance of the differences in CYP3A4 inhibition between the different molecular 
topological classes for basic and neutral compounds.  
Basic 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR 
1TR <0.0001 0.0049 <0.0001 <0.0001 <0.0001 
2TR - 0.1127 0.0307 <0.0001 <0.0001 
2TR+B_0 - - <0.0001 <0.0001 <0.0001 
2TR+B_1 - - - <0.0001 <0.0001 
2TR+B_2 - - - - 0.0010 
 
Neutral 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR 
1TR <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
2TR - 0.201 <0.0001 <0.0001 0.0016 
2TR+B_0 - - <0.0001 <0.0001 <0.0001 
2TR+B_1 - - - <0.0001 0.1472 
2TR+B_2 - - - - <0.0001 
  
Table S3. p-values calculated with the Wilcoxon rank-sum test displaying the statistical 
significance of differences in ClogP between the different molecular topological classes. All 
differences between the topological classes for Heavy atom count and  fMF were statistically 
significant (p<0.0001). 
ClogP 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR 
1TR 0.6726 <0.0001 0.0001 <0.0001 <0.0001 
2TR - <0.0001 <0.0001 <0.0001 <0.0001 
2TR+B_0 - - 0.4048 0.0001 <0.0001 
2TR+B_1 - - - <0.0001 <0.0001 
2TR+B_2 - - - - <0.0001 
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Abstract 
The influence of molecular topology on physico-chemical properties and on the probability of 
success in clinical trials has been proposed in earlier studies. Compounds with only one ring 
system were more frequently observed among drugs in comparison to compounds with 
reported biological activity in the literature and to clinical candidate compounds. Another 
study has identified compounds with only one ring system are much more frequent among 
human metabolites compared to other sources of molecules. To better understand how the 
molecular topology is influencing the drug discovery process, we have investigated the 
frequency of different molecular topologies in published patents. Our study shows that patent 
compounds with low lipophilicity and small size have on average fewer ring systems. The 
influence of the molecular topology on ligand efficiency (LE), ligand lipophilic efficiency 
(LLE) and Ligand-efficiency-dependent lipophilicity (LELP) was also analyzed and it was 
found that on average compounds with fewer ring system and in particular compounds with 
only one ring system show consistently better LE, LLE and LELP. The results suggest that 
compounds with fewer ring system have better properties that might contribute to a higher 
clinical success rate even after taken into account differences in target distribution between 
the different topological classes.  
 
Introduction 
Since the beginning of the genomics era in the 1990s, the drug discovery strategy has been 
largely transformed from low throughput in vivo based phenotypic screening cascade to a 
target centric high-throughput in vitro screening cascade. This paradigm shift has so far not 
been able to increase the productivity of pharmaceutical industry as a whole and recent data 
indicate that, only 10% of the compounds that are selected as clinical candidates will survive 
to the market.
1,2
 The complexity of the drug discovery process is well recognized. A 
successful drug discovery project involves optimization of multiple parameters, such as 
potency on the primary target, selectivity and absorption, distribution, metabolism, excretion 
and toxicity (ADMET) properties. It is a very difficult path beginning with hit identification, 
lead generation and followed by lead optimization to achieve the optimal molecular properties 
needed by a clinical candidate. For a molecule to reach clinical candidate selection, it should 
have a high potency on the primary target, high selectivity, a good ADMET property profile 
as well as a good PKPD (pharmaco-kinetic and pharmaco-dynamic) profile. High potency on 
the primary target is an important factor to optimize during the drug development process to 
reach an optimal PKPD profile. It contributes, in most cases, to a low required dose for 
reaching the desired pharmacological effect. Thus the risk of having compound related safety 
liabilities decreases. However, other factors like ADMET properties, target engagement and 
residence time are very important as well. In many cases high potency and good ADMET 
properties are very challenging to combine in one molecule. For example, the dependence of 
potency on molecular size and lipophilicity has been well described in the literature.
3-6
 
Finding the right balance between them
3,4
 is still a very challenging task for medicinal 
chemists.   
As a new descriptor for compound quality assessment, molecular topology class has been 
proposed. Molecular topology class is an extension of Murcko’s molecular framework 
concept.
7,8
 Comparing to Murcko molecular framework, it consists of only a few classes, 
which makes it possible to apply rigorous statistical methods to analyze the results in an 
informative way. In comparison a large dataset of molecules may consist of thousands of 
different molecular frameworks. Previously it has been observed that there is an enrichment 
of compounds with only one ring system (1TR) among drugs compared to clinical candidates 
and general bioactive compounds. This conclusion is still valid after correcting for any 
potential bias originating from lipophilicity (ClogP), molecular size and differences in target 
distribution among the different molecular topology classes.
7
 The study was further extended 
with the inclusion of natural product and human metabolites and it was found that they also 
were enriched with compounds having only one ring system. Further analysis showed that 
published compounds are getting less similar to human metabolites over time. These results 
might be due to the change in medicinal chemistry practice during the last decades. Analyzing 
the shift in how often different topological classes occur in medicinal chemistry publications 
indicated that this is the case. The influence of the molecular topology on the selectivity of 
drugs has also been investigated.
9
 Compounds with only one ring system were found to be 
more selective than compounds with two or more ring systems. To further understand the 
differences between molecular topology classes, it was decided to investigate a large set of 
compounds extracted from a commercial patent database. Pharmaceutical patents were chosen 
as the data source, since these compounds should have been reasonably well characterized by 
the organization filing the patent. It is also the major source for analyzing compounds 
synthesized and utilized in the pharmaceutical industry. It is acknowledged that an analysis of 
data from a patent database mixes different type of targets and assays, so the data needs to be 
analyzed carefully to remove this type of bias. The patent data was used to investigate the 
frequency of different topological classes as a function of size and lipophilicity and to 
investigate the influence of topology on efficiency indices for ligand-target binding which are 
commonly applied in the drug discovery process, such as ligand efficiency (LE), ligand 
lipophilic efficiency (LLE) and Ligand-efficiency-dependent lipophilicity (LELP).   
As it has been discussed earlier, screening of compounds purely on the potency could mean 
selecting compounds with poor ADMET properties.
3,4
 Ligand efficiency (LE)
10
 has been 
proposed as a measure for selecting lead compounds. Per definition LE is a method to 
normalize the potency with respect to the molecular size. It is therefore possible to compare 
potencies of compounds in a wide range of molecular size. LE is defined as: 
LE = ∆G / HEV     (Equation 1) 
Where ∆G = -RT ln Ki, Ki = XC50 / 2 and HEV is the number of heavy atoms.   
There are criticisms that LE does not completely eliminate the size bias.
5,6,11
   Despite of this, 
LE is still commonly used to assess the affinity of compounds for a target. Especially in 
fragment based drug design, LE is widely accepted and practically used, since this index gives 
priority to small molecules with relatively lower potency rather than large molecules with 
higher potency.
12,13 
  
Another useful ligand efficiency index is Ligand Lipophilicity Efficiency (LLE)
 14
, which is 
defined as:  
LLE = pXC50 – ClogP     (Equation 2) 
LLE can be used to improve the potency while keeping the lipophilicity low.
14
 It was shown 
by Tarcsay et al.
15
 that increasing potency during hit identification and lead optimization also 
increases lipophilicity in general. LLE is a useful index to control the lipophilicity while 
improving the potency, since high lipophilicity tends to cause adverse ADMET properties and 
high promiscuity.
14
 It has been shown that LLE differentiates between hits, leads, and drugs.
15
   
LE and LLE highlights low potency compounds with small size and low lipophilicity, which 
might otherwise be overlooked when analyzing hits from a high-throughput screening. The 
use of a small and less lipophilic molecule as a starting point is beneficial as the size and 
lipophilicity generally will be increased during the lead optimization process.
4,16
  
As ligand efficiency does not consider the lipophilicity and ligand lipophilicity efficiency 
does not consider the molecular size, Ligand-Efficiency-dependent LipoPhilicity index 
(LELP) has recently been proposed to address this issue.
16
 LELP is a descriptor which 
combines the three important factors, lipophilicity, molecular size, and potency into one 
descriptor. LELP is calculated using the following formula: 
LELP = ClogP / LE     (Equation 3) 
Where LE is the ligand efficiency 
It has been observed that LELP can differentiate between drugs from hits, leads and even 
from compounds that had entered phase II clinical trials, which was not possible to do using 
LLE.
15
 It has also been suggested that the combination of molecular mass and lipophilicity 
provides a better prioritization of compounds during the screening process.
3
 While LELP has 
not been used as widely in publications as LE and LLE, we still felt that it would be useful to 
include an efficiency indices that combines both size and lipophilicity in one measure in the 
analysis. Also other compound efficiency metrics were investigated like size-independent 
ligand efficiency (SILE).
6
 The results were found to be consistent with that of LE, LLE and 
LELP and therefore they will not further be discussed here.   
Thus LE, LLE and LELP have been shown to be useful indices to judge compound quality. In 
the current study, the influence of the molecular topology on LE, LLE and LELP for a set of 
compounds from the patent literature is investigated. The aim is to better understand why 
certain molecular topologies are more frequent among drugs than among general bioactive 
compounds. 
 
Material and Methods 
Data Sets  
All the data used in current study was retrieved from a commercial source.
17
 Compounds with 
a reported potency for at least one human target were extracted. In total 1,022,057 data points 
which correspond to bioactivity data (pXC50) for 695,322 unique structures and 972 human 
targets. Target classes represented in the dataset were GPCRs, Kinases, Ion Channels, 
Transporters, Proteases, Nuclear Hormone Receptors, Phosphotases, Oxidoreductases and 
Hydrolases. All compounds with a substructure composed of more than three amino acids 
were removed to assure there was no influence of patents covering peptides. 
Property Calculations  
 ClogP was calculated using a commercially available program.
18
 Molecular topology classes 
and the number of heavy atoms (i.e., non-hydrogen atoms) were calculated with an in-house 
C++ program.
19
 Wilcoxon rank-sum test
21
 was performed with the open source statistic 
package, Python-statlib.
22
  
 
Definition of molecular topology classes 
The molecular topology class definition
7 
is an extension of the molecular framework (MF) 
concept.
8
 A molecule is divided into three subunits: terminal ring systems (TR), a molecular 
bridge (B), and side chains. A terminal ring system refers to a ring system which has only one 
connection to other ring systems in the molecule. The molecular bridge connects all of the 
terminal rings. The difference between the definition of a molecular bridge and the definition 
of a linker is that a molecular bridge might include additional ring systems, while a linker 
does not include any ring system at all. Any ring system which is directly connected through 
linkers to more than one other ring system is regarded as part of the molecular bridge. Thus, 
the MF is the combination of the terminal rings and the molecular bridge. Side chains refer to 
atoms that do not belong to the MF. Some examples of different topological classes are shown 
in Figure 1. The 2TR+B class is subdivided according to the number of ring systems in the 
molecular bridge to further enhance the analysis. In this study,  1TR, 2TR, 2TR+B and 
3TR+B topology classes were considered. More complicated classes such as 4TR+B, 5TR+B 
were excluded due to their low occurrence in the dataset. 
 
Result and Discussion 
It is important to first investigate if there are differences in the activity data reported for the 
different topological classes. The distributions of the reported potencies (pXC50) for the six 
molecular topology classes are shown in Figure 2. The activity distribution is fairly similar for 
all classes, approximately 30% of the compounds have high potency (pXC50 ≤ 7.0), 
approximately 28 % have an pXC50 between 7.0 and 6.0 and the rest has mainly potencies in 
the range between 6.0 and 5.0. Compounds having a 1TR topology has slightly higher 
reported averaged potency than compounds from the other topology classes. There are also 
significant differences in the number of reported molecules. The class 2TR+B_1 has the most 
number of reported molecules, roughly 274,000 molecules, while 1TR has only 24,000 
reported molecules. It reinforces the observations from an earlier study, which indicated a lot 
of 2TR+B and 3TR+B compounds are synthesized in modern medicinal chemistry programs. 
These compounds are then identified in screening campaigns and thereafter followed-up in 
drug discovery projects and accordingly patented. In order to investigate the influence of the 
lipophilicity for the dataset, the same set was binned according to ClogP for each topological 
class. As is seen in Figure 3a, distribution of the number of compounds differs a lot between 
the different topological classes. The 1TR class has a much higher proportion of molecules 
with a reported low ClogP compared to the other classes. Compounds from patents will reflect 
what type of compounds that have been found as hits in screening campaigns and followed-up 
with medicinal chemistry resources. The data shows that compounds identified from the 1TR 
class are on average less lipophilic. Similarly it was investigated how the distribution of 
molecules for the different topological classes varies as a function of their size. The trend is 
clear; compounds with fewer ring systems are generally smaller. Compounds with one ring 
system (1TR) are the smallest, while compounds with two ring system are in the middle (2TR 
and 2TR+B_0). This result is not surprised since in general the molecular size increases with 
increasing number of ring systems. Thus reported 1TR compounds are both less lipophilic and 
smaller than compounds from the other topological classes. However, in the Figures 3, the 
potency is not taken into account. Thus the identified high frequency of compounds belonging 
to the 1TR topological class might consist of weakly active compounds, even though 1TR 
compounds are on average slightly more active than compounds from other topological 
classes as shown in Figure 2. The average potency as a function of lipophilicity and size is 
plotted in Figure 4a and 4b. For ClogP values above 2.0, compounds belonging to the 1TR 
class are the most potent and accordingly have the best LLE. For ClogP below 2.0, 3TR+B 
has the highest potency; visual inspection of the compounds revealed that for the 3TR+B, 
there exist a set of highly potent peptidomimetic compounds with low ClogP published. 
However, as already shown in Figure 3a the fraction of compounds for the 3TR+B class with 
a low ClogP is very low. To better understand the interrelationship between activity, size and 
lipophilicity, the LE was plotted against ClogP. It is seen that, for all ClogP values, the 
compounds from the 1TR topological class has the highest LE values followed by compounds 
from the 2TR topological class. Compounds from the 3TR topological class have the lowest 
LE. Thus the (peptidomimetic) compounds identified form the 3TR+B class with high 
potency and low ClogP has a low LE, due to their large size. In conclusion, compounds from 
the 1TR class have overall the best properties taking size and lipophilicity into account. More 
elaborated graphs describing the relationship between potency, topological class, size and 
lipophilicity are given in Figures S1-S4. 
In this current study, it is of our interest to further explore what is the impact of molecular 
topology class on binding efficiency indices such as LE, LLE and LELP (Equations 1-3). LE, 
LLE and LELP values for different molecular topology class were compared (Figure 5). As 
already shown in Figure 2 compounds with a 1TR topology has slightly higher reported 
potencies, however, the differences in LE, LLE and LELP are significantly larger. Besides 
being slightly more potent, 1TR compounds are on average significantly smaller and less 
lipophilic which gives rise to the differences in LE, LLE and LELP.  
However, it should be noted that so far the analysis does not take into account that compounds 
from different topological classes might be reported from different targets. In order to exclude 
that the identified results are affected by different topological classes modulates different 
targets, a separate analysis needs to be done where the median LE, LLE and LELP are 
calculated for each target and topological class. We selected only targets where there are at 
least 10 compounds known for each of the six topological classes. In total, 190 targets 
fulfilled this requirement. For each of these selected targets, the median values of LE, LLE 
and LELP of every molecular topology class were calculated (Figure 6). Figure 6 shows that 
compounds belonging to the 1TR class has the highest median values for both LE and LE and 
the lowest median value for LELP. The topological classes with several ring systems have the 
lowest LE and LLE and highest LELP. Thus the results here mirror the results in Figure 5, 
when comparing the median LE, LLE and LELP values for the 190 targets with at least 10 
compounds from each target class.  Each pair of topological classes was also compared for all 
targets where at least one compound from each of the two topological classes is reported. The 
results are given in Table S1 and are consistent with the results of Figure 6. The most 
common target classes (Enzymes, GPCRs, Ion Channels and NHRs) were also investigated 
individually for each pair of topological classes and the results are shown in Table S2-S5 
confirming the earlier results. Compounds belonging to the 1TR class have on average better 
LE, LLE and LELP for each target class. Thus the observed trends of LE, LLE and LELP 
with molecular topology in Figure 5 are still valid after correcting for any potential target 
bias. Some structure examples are shown in Figure 7. Here we have chosen a GPCR, 
Histamine receptor type 3 (H3), to illustrate how representative molecules look like. It should 
be noted that H3 has histamine as an endogenous agonist, which belongs to the 1TR 
molecular topology class; so it is not surprising that also synthetic 1TR compounds show high 
pXC50 towards this receptor.  
 
Conclusions  
It has been shown in earlier studies that the molecular topology influences clinical success 
and selectivity and the distribution among the topological classes are very different for 
different data sources. To better understand how clinical success is influenced by topological 
class, an analysis has been performed on bioactivity data reported in the patent literature. It 
was first observed that compounds from the 1TR topological class are much less reported in 
patents than several other topological classes. Thereafter how the distribution of the different 
topological classes changes with ClogP and HEV was further analyzed and it was found that 
compounds belonging to the 1TR class are more likely to be smaller and less lipophilic than 
compounds with two ring systems (2TR and 2TR+B_0) and even more so compared to 
compounds with three or more ring systems (2TR+B_1, 2TR+B_2 and 3TR). It was also 
shown that at a constant size or lipophilicity, compounds with a 1TR ring system were 
generally slightly more active. An exception is compounds belonging to the 3TR+B class with 
low lipophilicity. They are mainly peptidomimetic compounds, and are the most potent 
compared to compounds belonging to other topology classes. However, only a small fraction 
of the 3TR+B class compounds has low lipophilicity. Most of the compounds have a high 
lipophilicity. Our studies also show that compounds with fewer ring systems have better LE, 
LLE and LELP. These trends are not due to differences in target distribution for compounds 
belonging to different topological classes. Thus the conclusions still hold even after taking 
into account that the distribution of active compounds for different molecular topology classes 
might be different for different targets. The results are also valid for all the major target 
classes. The reason that compounds from the 1TR topological class have better LE, LLE and 
LELP is two-fold, first, they have on average a slightly higher potency than compounds from 
the other topological classes even after taking size and lipophilicity into account. Second, 
compounds belonging to the 1TR topological class have generally lower lipophilicity and 
smaller size comparing with other topology classes among patented compounds. The stronger 
affinity for compounds with 1TR topology might be related to the prominence of compounds 
with 1TR topology among natural products and human metabolites. Small molecules present 
in nature might have evolved to interact strongly with their target and to accomplish that a 
1TR topology might have been preferred by the evolution. As a consequence, synthetic 
molecules with a 1TR topology might also interact more strongly with their protein target. 
However, the observation that compounds with a 1TR topology has better LE and LLE is 
empirical. Modeling of ligand-protein interactions is still very difficult as evidenced by the 
difficulties to accurately calculate the free energy for the ligand-protein complex. It is also an 
interesting observation that the fraction of compounds reported with a 1TR topology is much 
higher among small and hydrophilic compounds. This might be related to the modern 
medicinal chemistry practice that mainly produces 2TR+B and 3TR+B compounds. These 
compounds are then identified as hits in high-throughput screening and used in drug discovery 
project and thereafter reported in the patents. However, the results in this article indicate that 
screening more human metabolites and other natural products might be an approach to 
improve the success in drug discovery projects. These sets are enriched with compounds 
belonging to the 1TR topological class and might therefore produce screening hits that can be 
optimized to compounds with good LE and LLE. It should be noted that all retrospective 
analysis of patented compounds will per definition reflect the historical target space that has 
been exploited in drug discovery projects, thus there is no guarantee that the identified 
conclusions will hold for future drug discovery projects that might pursue different types of 
targets. 
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Figure 1. Examples of compounds from different topological classes. (TR = Terminal Ring(s), 
B = Bridge).  Purple is showing the terminal rings and orange is showing the molecular bridge 
in each compound.   
  
 Colored by potency (pXC50)  
 
 
Figure 2. The potency distribution for the six topological classes.  The number of molecules 
represented by each pie-chart is shown in black and the average pXC50 values are shown in 
red. 
  
 (a)  
  (b) 
Figure 3. The percentage of compounds in the six topological classes versus (a) ClogP and (b) 
heavy atom count (HEV).    
0 
10 
20 
30 
40 
50 
≤ 0.0 0.0 - 
1.0 
1.0 - 
2.0 
2.0 - 
3.0 
3.0 - 
4.0 
4.0 - 
5.0 
> 5.0  
%
 c
o
m
p
o
u
n
d
s 
ClogP 
1TR 
2TR 
2TR+B_0 
2TR+B_1 
2TR+B_2 
3TR+B 
0 
10 
20 
30 
40 
50 
60 
70 
≤ 15 16 - 19 20 - 23 24 - 27 28 - 31 32 - 35 ≥ 36 
%
 c
o
m
p
o
u
n
d
s 
HEV 
1TR 
2TR 
2TR+B_0 
2TR+B_1 
2TR+B_2 
3TR+B 
(a)  (b)  
(c)  
 
Figure 4. The relationship between (a) ClogP and mean pXC50, (b) Number of heavy atoms 
(HEV) and mean pXC50, and (c) ClogP and mean LE for the different topological classes. 
  
(a) Potency (pXC50) (b)  Ligand Efficiency (LE) 
(c)  Ligand Lipophilic Efficiency (LLE) (d) Ligand-efficiency-dependent lipophilicity 
(LELP) 
 
 
Figure 5. The  (a) pXC50, (b) LE, (c) LLE and (d) LELP  distributions for each topological 
class. Count is the number of molecules for each topological class. 
(a) Potency (pXC50) (b) Ligand Efficiency (LE) 
(c) Ligand Lipophilic Efficiency (LLE) (d) Ligand-efficiency-dependent lipophilicity 
(LELP)  
Figure 6. The distribution of the median (a) pXC50, (b) LE, (c) LLE and (d) LELP for each 
target and topological class.  Count is the number of targets which have more than 10 
compounds for each topological class. 
  
(a) 1TR 
pXC50: 7.70,     LE: 0.95, 
LLE: 7.22,      LELP: 0.49 
(b) 2TR  
pXC50: 7.72,     LE: 0.48, 
LLE: 3.84,      LELP: 8.11 
(c) 2TR+B_0  
pXC50: 7.55,     LE: 0.40, 
LLE: 3.20,      LELP: 11.0 
(d) 2TR+B_1  
pXC50: 7.64,     LE: 0.33, 
LLE: 3.03,      LELP: 14.2 
(e) 2TR+B_2  
pXC50: 7.55,     LE: 0.26, 
LLE: 2.92,      LELP: 17.6 
(f) 3TR+B  
pXC50: 7.85,     LE: 0.30, 
LLE: 1.70,      LELP: 20.7 
Figure 7. Representative structures for Histamine receptor H3. The median values for each 
topology are: 1TR: pXC50 5.85, LE 0.52, LLE 3.67, LELP 4.35, 2TR: pXC50 5.70, LE 0.37, 
LLE 2.94, LELP 8.88, 2TR+B_0: pXC50 5.70, LE 0.33, LLE 2.76, LELP 8.48, 2TR+B_1: 
pXC50 5.70, LE 0.31, LLE 2.86, LELP 10.7, 2TR+B_2: pXC50 5.70, LE 0.25, LLE 2.65, 
LELP 12.3, 3TR+B: pXC50 5.70, LE 0.24, LLE 2.77, LELP 14.2. 
 
  
 Colored by potency 
(pXC50)  
Figure S1. The potency distribution of the six topological classes for different ClogP intervals.  
The number of molecules represented by each pie-chart is shown in black and the average 
pXC50 values are shown in red. 
  
 Colored by potency  
(pXC50)  
Figure S2. The potency distribution for the six topological classes for different heavy atom 
count (HEV).  The number of molecules represented by each pie-chart is shown in black and 
the average pXC50 values are shown in red. 
  
 Colored by 
 molecular topology 
 class 
Figure S3. The topological class distribution for the five potency ranges and different ClogP 
intervals.  The number of molecules for each pie-chart is indicated in the figure. 
  
 Colored by 
 molecular topology 
class 
Figure S4. The topological class distribution for five different potency ranges and different 
number of heavy atoms (HEV).  The number of molecules represented by each pie-chart is 
also shown.  
  
 Table S1. The differences between the median of LE, LLE and LELP between two molecular 
topology classes for all targets that have compounds from both topological classes. The 
numbers in the parentheses are the number of targets, which the two topological classes have 
in common.   
ΔLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR -0.03 (466) -0.06 (553) -0.09 (548) -0.11 (465) -0.12 (442) 
2TR - -0.03 (505) -0.06 (521) -0.10 (472) -0.10 (434) 
2TR+B_0 - - -0.03 (641) -0.06 (534) -0.07 (510) 
2TR+B_1 - - - -0.03 (584) -0.04 (543) 
2TR+B_2 - - - - -0.01 (490) 
 
ΔLLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR -0.73 (466) -0.77 (553) -1.27 (548) -1.62 (465) -2.04 (442) 
2TR - 0.01 (505) -0.56 (521) -0.89 (472) -1.13 (434) 
2TR+B_0 - - -0.52 (641) -0.80 (534) -1.12 (510) 
2TR+B_1 - - - -0.35 (584) -0.73 (543) 
2TR+B_2 - - - - -0.37 (490) 
 
ΔLELP 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR 2.05 (466) 3.08 (553) 6.02 (548) 9.78 (465) 11.52 (442) 
2TR - 0.99 (505) 4.12 (521) 7.90 (472) 9.80 (434) 
2TR+B_0 - - 3.15 (641) 6.69 (534) 8.36 (510) 
2TR+B_1 - - - 3.46 (584) 5.33 (543) 
2TR+B_2 - - - - 2.34 (490) 
  
Table S2. The differences between the median of LE, LLE and LELP between two molecular 
topology classes for enzymes that have compounds from both topological classes. The 
numbers in the parentheses are the number of targets.   
ΔLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR -0.02 (294) -0.05 (362) -0.08 (361) -0.09 (298) -0.10 (275) 
2TR - -0.02 (310) -0.06 (323) -0.10 (286) -0.10 (255) 
2TR+B_0 - - -0.04 (406) -0.06 (323) -0.07 (300) 
2TR+B_1 - - - -0.03 (360) -0.04 (319) 
2TR+B_2 - - - - -0.01 (285) 
 
ΔLLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR -0.81 (294) -0.61 (362) -1.17 (361) -1.45 (298) -1.85 (275) 
2TR - 0.29 (310) -0.52 (323) -0.80 (286) -1.07 (255) 
2TR+B_0 - - -0.55 (406) -0.89 (323) -1.19 (300) 
2TR+B_1 - - - -0.35 (360) -0.73 (319) 
2TR+B_2 - - - - -0.35 (285) 
 
ΔLELP 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR 1.83 (294) 2.44 (362) 5.13 (361) 8.26 (298) 10.39 (275) 
2TR - 0.28 (310) 3.77 (323) 7.52 (286) 9.59 (255) 
2TR+B_0 - - 3.38 (406) 6.71 (323) 8.32 (300) 
2TR+B_1 - - - 3.44 (360) 5.40 (319) 
2TR+B_2 - - - - 2.14 (285) 
 
  
Table S3. The differences between the median of LE, LLE and LELP between two molecular 
topology classes for GPCRs that have compounds from both topological classes. The numbers 
in the parentheses are the number of targets.   
ΔLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR -0.06 (116) -0.10 (126) -0.15 (123) -0.18 (119) -0.20 (114) 
2TR - -0.04 (130) -0.06 (136) -0.10 (134) -0.10 (125) 
2TR+B_0 - - -0.03 (158) -0.06 (153) -0.07 (146) 
2TR+B_1 - - - -0.03 (166) -0.04 (155) 
2TR+B_2 - - - - -0.01 (151) 
 
ΔLLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR -0.73 (116) -1.22 (126) -1.83 (123) -1.87 (119) -2.74 (114) 
2TR - -0.55 (130) -0.59 (136) -0.99 (134) -1.26 (125) 
2TR+B_0 - - -0.28 (158) -0.70 (153) -1.07 (146) 
2TR+B_1 - - - -0.34 (166) -0.63 (155) 
2TR+B_2 - - - - -0.42 (151) 
 
ΔLELP 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR 2.78 (116) 5.16 (126) 8.33 (123) 11.70 (119) 15.10 (114) 
2TR - 2.43 (130) 4.41 (136) 8.28 (134) 10.09 (125) 
2TR+B_0 - - 2.79 (158) 6.61 (153) 8.85 (146) 
2TR+B_1 - - - 3.05 (166) 4.91 (155) 
2TR+B_2 - - - - 2.68 (151) 
  
Table S4. The differences between the median of LE, LLE and LELP between two molecular 
topology classes for ion channels that have compounds from both topological classes. The 
numbers in the parentheses are the number of targets.   
ΔLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR -0.06 (35) -0.11 (43) -0.13 (41) -0.19 (29) -0.17 (30) 
2TR - -0.03 (44) -0.06 (40) -0.09 (33) -0.09 (32) 
2TR+B_0 - - -0.03 (49) -0.07 (37) -0.06 (38) 
2TR+B_1 - - - -0.04 (36) -0.03 (41) 
2TR+B_2 - - - - 0.00 (33) 
 
ΔLLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR -0.71 (35) -0.91 (43) -1.46 (41) -2.70 (29) -1.84 (30) 
2TR - -0.09 (44) -0.61 (40) -1.03 (33) -1.19 (32) 
2TR+B_0 - - -0.77 (49) -1.21 (37) -1.42 (38) 
2TR+B_1 - - - -0.36 (36) -0.83 (41) 
2TR+B_2 - - - - -0.41 (33) 
 
ΔLELP 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR 2.94 (35) 4.80 (43) 6.76 (41) 10.39 (29) 12.66 (30) 
2TR - 0.40 (44) 4.25 (40) 8.72 (33) 10.34 (32) 
2TR+B_0 - - 3.76 (49) 7.99 (37) 8.64 (38) 
2TR+B_1 - - - 4.26 (36) 5.79 (41) 
2TR+B_2 - - - - 1.44 (33) 
  
Table S5. The differences between the median of LE, LLE and LELP between two molecular 
topology classes for NHRs that have compounds from both topological classes. The numbers 
in the parentheses are the number of targets.   
ΔLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR 0.01 (21) -0.05 (22) -0.08 (23) -0.09 (19) -0.10 (23) 
2TR - -0.05 (21) -0.07 (22) -0.09 (19) -0.08 (22) 
2TR+B_0 - - -0.04 (28) -0.05 (21) -0.04 (26) 
2TR+B_1 - - - -0.02 (22) -0.02 (28) 
2TR+B_2 - - - - 0.00 (21) 
 
ΔLLE 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR 0.32 (21) -0.22 (22) -0.55 (23) -1.10 (19) -1.42 (23) 
2TR - -0.64 (21) -1.09 (22) -0.63 (19) -1.32 (22) 
2TR+B_0 - - -0.51 (28) -0.38 (21) -0.86 (26) 
2TR+B_1 - - - -0.11 (22) -0.71 (28) 
2TR+B_2 - - - - -0.38 (21) 
 
ΔLELP 2TR 2TR+B_0 2TR+B_1 2TR+B_2 3TR+B 
1TR -0.03 (21) 3.93 (22) 5.65 (23) 11.90 (19) 11.88 (23) 
2TR - 3.13 (21) 5.79 (22) 11.36 (19) 10.02 (22) 
2TR+B_0 - - 4.17 (28) 5.95 (21) 6.54 (26) 
2TR+B_1 - - - 3.70 (22) 3.34 (28) 
2TR+B_2 - - - - 1.63 (21) 
 
 
